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Background: Insulin-like growth factor-binding protein 7 (IGFBP-7) is able to interact with insulin-like growth factor
1 (IGF-1) as well as insulin. Previous studies have suggested that serum IGFBP-7 levels may be associated with insulin
resistance in type 2 diabetes (T2D). This study aimed to evaluate IGFBP-7 serum protein and IGFBP7 DNA methylation
levels in the subjects with and without T2D.
Results: A total of 340 Swedish subjects including 100 newly diagnosed T2D patients (50 women/50 men), 100
age-matched nondiabetic control subjects (50/50) and 140 treated T2D patients (54/86) were studied. Serum IGFBP-7
levels were measured with a novel ELISA. IGF1, IGFBP-1, and insulin were determined by in-house radioimmunoassays.
DNA methylation levels in the IGFBP7 gene were analyzed with a bisulfite-pyrosequencing technique. Serum IGFBP-7
protein levels were similar among nondiabetic subjects, newly diagnosed, and treated T2D patients and were not correlated
with IGFBP7 DNA methylation. However, IGFBP7 DNA methylation was increased in men with newly diagnosed T2D
compared with nondiabetic controls (17.6% vs. 12.5%, P < 0.01). Serum IGFBP-7 levels correlated (r = 0.331, P = 0.019)
with serum IGFBP-1 levels, a marker of insulin production, in men but not women with newly diagnosed T2D.
Conclusions: This study demonstrates for the first time that IGFBP7 DNA methylation levels are increased in Swedish
men with newly diagnosed T2D. The correlation between IGFBP-7 and IGFBP-1 suggests that low IGFBP-7 may be asso-
ciated with insulin resistance in T2D.
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Insulin-like growth factor 1 (IGF-1) is a polypeptide hor-
mone, which shares structural homology and down-
stream signaling pathways with insulin. Several studies
have demonstrated that IGF-1 has insulin-like effects,
stimulating peripheral uptake of glucose and free fatty
acids [1-3]. Low levels of serum IGF-1 are associated
with an increasing risk of developing type 2 diabetes
(T2D) and obesity [4,5]. IGF-1 circulates in blood pre-
dominantly complexed to specific IGF-binding proteins
(IGFBP-1). There are six binding proteins (IGFBP-1 to
6) exhibiting high affinity to IGF-1 [1-3]. IGFBP-1 has* Correspondence: harvest.gu@ki.se
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reproduction in any medium, provided the orbeen shown to prolong the half-life of IGF-1 and IGF-2.
Elevations in insulin suppress the hepatic production of
IGFBP-1, resulting in decreased circulating levels. Circulat-
ing IGFBP-1 levels are inversely correlated with 24-hour
insulin secretion, insulin sensitivity, and an increased risk
of cardiovascular diseases [6-9]. Finally, low IGFBP-1 levels
may be permissive for the development of metabolic dis-
eases, such as T2D, obesity, and related cardiovascular
complications [10-13].
IGFBP-7 (also known as IGFBP-rP1, MAC25, PSF,
TAF, FSTL2, or PGI2-stimulating factor) is an additional
member of the IGFBP family. Unlike the high affinity of
the other six IGFBPs, IGFBP-7 exhibits low affinity for
IGF-1, but has a relatively high affinity for insulin
[14,15]. It is hypothesized that IGFBP-7 may interfere
with insulin action and subsequently play a role in theThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cation. There are three reports evaluating IGFBP-7 in
T2D. In 2006, Lopez-Bermejo et al. [16] measured
serum IGFBP-7 levels in 43 men with T2D and 113 nondi-
abetic subjects and found increased serum IGFBP-7 levels
to be associated with insulin resistance. One year later, the
same research group [17] detected serum IGFBP-7 levels
in 24 male T2D patients with high-ferritin and suggested
that vascular function was linked to serum IGFBP-7
levels in these patients. In 2008, Kutsukake et al. [18]
developed a novel IGFBP-7 ELISA using two IGFBP-7
antibodies and analyzed serum IGFBP-7 levels in 33
male hemodialysis patients, including 18 patients with
and 15 patients without T2D. Their data indicated that
hemodialysis patients with T2D had higher serum
IGFBP-7 levels than the hemodialysis patients without
T2D.
These three studies suggested a possible association
between IGFBP-7 and T2D. However, the sample sizes
of T2D patients in the studies were relatively small and
no female patient with T2D was included. Furthermore,
recent studies have shown that epigenetic changes pro-
vide a link for the translation of environmental expo-
sures into susceptibility for T2D. Epigenetic studies may
provide useful information for a better understanding of
the pathogenesis of T2D [19-21]. To our knowledge, no
epigenetic study of the IGFBP7 gene in T2D has been re-
ported. In this study, we have determined serum IGFBP-7
levels in a cohort consisting of 340 Swedish men and
women including newly diagnosed T2D patients, age-
matched nondiabetic controls and anti-diabetic treated
T2D patients. In addition, we analyzed levels of IGFBP7
DNA methylation. Our aims were to evaluate serum pro-
tein and DNA methylation levels of IGFBP-7 in T2D.
Results
Serum IGFBP-7 levels and correlation with IGFBP-1
Serum IGFBP-7 protein levels in both men and women
with normal glucose tolerance (NGT), newly diagnosed
T2D, and anti-diabetic treated T2D are presented in
Table 1. No statistical significant difference in serum
IGFBP-7 levels was found between the three groups, nei-
ther in analyses when data for men and women were
combined nor in sex-specific analyses.
We then analyzed the correlations between serum
IGFBP-7 protein levels and other laboratory variables,
including fasting glucose, fasting insulin, homeostasis
model of assessment insulin resistance (HOMA-IR),
IGF-1, and IGFBP-1. In patients with newly diagnosed
T2D, there was no correlation between IGFBP-7 and
fasting glucose, fasting insulin, or HOMA-IR. However,
a tendency towards a significant negative correlation was
found between IGFBP-7 and IGF-1 (r = −0.258, P = 0.070)
in men with newly diagnosed T2D (Table 2). Furthermore,IGFBP-7 correlated positively with IGFBP-1 in these male
patients (r = 0.331, P = 0.019, Figure 1). Similar correla-
tions were not observed in newly diagnosed women with
newly diagnosed T2D. Apart from these correlations,
none was observed.
DNA methylation levels of the IGFBP7 gene
To further investigate whether IGFBP-7 plays a role in
T2D, we analyzed DNA methylation of the IGFBP7 gene
in men with NGT or newly diagnosed T2D, respectively.
Figure 2 demonstrates that IGFBP7 DNA methylation
levels were significantly increased in newly diagnosed T2D
patients compared with NGT subjects at all three CpG
sites (P1: 10.4% vs. 6.2%; P2: 14.3% vs. 8.6% and P3: 44.4%
vs. 22.7%, all P < 0.01). Combined data from all three CpG
sites showed that genomic DNA methylation levels of the
IGFBP7 gene in T2D were increased compared with
subjects with NGT (17.6% vs. 12.5%, P < 0.01).
Discussion
We have determined serum IGFBP-7 levels in newly di-
agnosed T2D patients, age-matched nondiabetic controls
and anti-diabetic treated T2D patients and for the first
time found a correlation between IGFBP-7 and IGFBP-1
in men with newly diagnosed T2D. Moreover, we ana-
lyzed the levels of IGFBP7 DNA methylation and found
that IGFBP7 DNA methylation levels were higher in
male T2D patients than in nondiabetic subjects.
IGFBP-7 is widely expressed in various tissues, includ-
ing the brain, lung, prostate, and gastrointestinal tract
and the protein is also detectable in the circulation
[14,15]. In this study, we measured serum IGFBP-7 pro-
tein levels using a novel sandwich ELISA protocol [18].
Data demonstrated that serum IGFBP-7 protein mean
concentrations were 19 to 22 μg/l in Swedish men with
and without T2D and 18.8 to 20.0 μg/l in women. Fur-
ther, no statistically significant difference in serum
IGFBP-7 protein levels was found between the subjects
with NGT and newly diagnosed T2D or anti-diabetic
treated T2D patients. Previously, Lopez-Bermejo et al.
[16] reported that the mean levels of serum IGFBP-7 in
Spanish men without and with T2D were 26 to 28 μg/l
using an enzyme-linked immune-sorbent assay. Data in
their study implicated that IGFBP-7 was associated with
insulin resistance [16]. However, the association of
IGFBP-7 with insulin resistance (determined as HOMA-
IR) was not observed in our study. The difference in results
may be due to sample size and the selection criteria of the
T2D patients. In this study, the sample size was larger and
the patients were newly diagnosed, as compared with pre-
vious reports [16-18].
Low serum IGFBP-1 levels are found to be associated
with hyperinsulinemia, insulin sensitivity, development
of T2D, and obesity [10-12]. In this study, low serum
Table 1 Clinical and laboratory variables in Swedish subjects with normal glucose tolerance and in the patients with
type 2 diabetes
Stockholm Diabetes Prevention Program Kronan
Normal glucose
tolerance
Newly diagnosed type 2
diabetes
Type 2 diabetes
N = All (women/men) 100 (50/50) 100 (50/50) 140 (54/86)
Age (years) All 58 (57 to 58) 58 (57 to 58) 61 (60 to 63)†††§§§
Women 57 (55 to 58) 57 (55 to 58) 62 (60 to 64)†††§§§
Men 58 (57 to 59) 58 (57 to 59) 62 (60 to 63)††§§
Body mass index (kg/m2) All 24.4 (23.8 to 25.1) 30.7 (29.4 to 31.9)††† 29.3 (28.6 to 30.1)†††
Women 23.4 (22.7 to 24.1) 32.2 (30.2 to 34.3)††† 29.7 (28.4 to 30.9)†††§
Men 25.4 (24.4 to 26.4)*** 29.1 (27.8 to 30.4)†††* 29.1 (28.1 to 30.2)†††
Waist and hip ratio All 0.86 (0.84 to 0.87) 0.93 (0.92 to 0.94)††† 0.95 (0.94 to 0.96)†††§
Women 0.82 (0.80 to 0.83) 0.90 (0.88 to 0.91)††† 0.90 (0.89 to 0.92)†††
Men 0.90 (0.88 to 0.91)*** 0.96 (0.95 to 0.98)†††*** 0.98 (0.97 to 0.99)†††***
Systolic blood pressure (mm Hg) All 130 (127 to 134) 146 (143 to 150)††† 147 (144 to 150)†††
Women 129 (124 to 133) 147 (141 to 152)††† 149 (145 to 154)†††
Men 132 (126 to 137) 146 (141 to 150)††† 146 (142 to 150)†††
Diastolic blood pressure (mm Hg) All 80 (78 to 82) 87 (85 to 90)††† 83 (81 to 84)§§§
Women 79 (77 to 82) 86 (83 to 89)†† 81 (78 to 83)§
Men 82 (79 to 84) 89 (86 to 92)††† 84 (82 to 86)§
Fasting glucose (mmol/l) All 4.8 (4.7 to 4.9) 6.8 (6.4 to 7.1)††† 9.0 (8.5 to 9.5)†††§§§
Women 4.6 (4.4 to 4.7) 6.6 (6.2 to 6.9)††† 9.2 (8.4 to 9.9)†††§§§
Men 5.0 (4.9 to 5.1)*** 6.9 (6.4 to 7.5)††† 8.9 (8.2 to 9.5)†††§§§
Fasting insulin (pmol/l)a All 73 (68 to 78) 140 (126 to 156)††† 135 (124 to 147)†††
Women 70 (64 to 76) 150 (130 to 173)††† 138 (123 to 154)†††
Men 77 (69 to 85) 131 (112 to 154)††† 133 (118 to 150)†††
Homeostasis model of assessment: insulin
resistancea
All 2.56 (2.37 to 2.78) 6.86 (6.03 to 7.79) 8.53 (7.66 to 9.50)†††§
Women 2.33 (2.11 to 2.59) 7.20 (6.09 to 8.52) 9.00 (7.78 to 10.41)†††
Men 2.82 (2.49 to 3.18)* 6.52 (5.35 to 7.96) 8.25 (7.09 to 9.60)†††
IGF-I (μg/l)a All 156 (147 to 167) 154 (144 to 165) 117 (107 to 128)†††§§§
Women 154 (141 to 167) 157 (143 to 172) 122 (106 to 141)†§§
Men 159 (145 to 175) 152 (138 to 167) 114 (102 to 128)†††§§§
IGFBP-1 (μg/l)a All 42 (38 to 47) 23 (20 to 26)††† 17 (14 to 20)†††§§
Women 57 (50 to 65) 28 (24 to 33)††† 18 (14 to 22)†††§§
Men 31 (27 to 37)*** 19 (16 to 23)††** 16 (13 to 20)†††
IGFBP-7 (μg/l)a All 20.5 (18.7 to 22.3) 19.6 (17.8 to 21.5) 19.2 (17.9 to 20.6)
Women 19.0 (16.8 to 21.4) 20.0 (17.0 to 23.5) 18.8 (16.7 to 21.7)
Men 22.1 (19.4 to 25.1) 19.2 (17.3 to 21.3) 19.5 (17.8 to 21.3)
Data were expressed as means (95% confidence interval (CI)) for normally distributed variables and as geometric means (95% CI) for anon-normally distributed
variables; Comparison between the three groups was performed by one-way analysis of variance (ANOVA), and if significant followed by Tukey’s post-hoc test;
†P < 0.05, ††P < 0.01, †††P < 0.001 vs. Stockholm Diabetes Prevention Program NGT and §P < 0.05, §§P < 0.01, §§§P < 0.001 vs. Stockholm Diabetes Prevention
Program type 2 diabetes; Comparison of men and women within groups was performed by unpaired t test; *P < 0.05, **P < 0.01, ***P < 0.001.
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levels in men with newly diagnosed T2D. We acknow-
ledge that this observation may not be causal. Never-
theless, we have a hypothesis that low IGFBP-7 levels
may be related to increased insulin and consequentlyassociated to insulin resistance. However, further mechan-
istic investigations are needed to test this hypothesis.
Several studies have demonstrated that increased DNA
methylation levels of the IGFBP7 gene are associated
with colorectal cancers and lung and prostate cancer.
Table 2 Univariate correlations between IGFBP-7 and other laboratory variables in Swedish subjects with normal glu-
cose tolerance and newly diagnosed type 2 diabetes
Normal glucose tolerance Newly diagnosed type 2 diabetes
All Women Men All Women Men
n = 100 n = 50 n = 50 n = 100 n = 50 n = 50
Fasting glucose r = 0.016 r = −0.158 r = 0.042 r = 0.016 r = −0.158 r = 0.042
P = 0.877 P = 0.273 P = 0.771 P = 0.877 P = 0.273 P = 0.771
Fasting insulin a r = 0.080 r = 0.115 r = 0.013 r = 0.039 r = 0.136 r = −0.107
P = 0.432 P = 0.427 P = 0.929 P = 0.702 P = 0.348 P = 0.462
HOMA-IR a r = 0.068 r = 0.047 r = 0.016 r = 0.012 r = 0.137 r = − 0.158
P = 0.499 P = 0.745 P = 0.914 P = 0.904 P = 0.344 P = 0.273
IGF-I a r = 0.053 r = 0.102 r = −0.004 r = −0.144 r = −0.080 r = −0.258
P = 0.599 P = 0.480 P = 0.977 P = 0.153 P = 0.583 P = 0.070
IGFBP-1 a r = 0.003 r = 0.149 r = 0.075 r = 0.114 r = −0.071 r = 0.331
P = 0.978 P = 0.301 P = 0.607 P = 0.261 P = 0.626 P = 0.019
aLog-transformed before analyses.
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genesis of these cancers, mainly through inactivation of
its DNA methylation [22-25]. DNA methylation is in-
volved in the regulation and expression of genes [26].
This epigenetic mechanism is believed to be a contribut-
ing factor to pathological conditions, such as T2D [19-21].
In this study, we have, for the first time, provided evidence
that DNA methylation levels in the IGFBP7 gene are in-
creased in Swedish men with newly diagnosed T2D. This
finding implicates that IGFBP7 DNA methylation may be
associated with early diagnosis of T2D. Generally, DNA
methylation of cytosine residues in CpG di-nucleotidesIGFBP-1 (µg/L)












r = 0.331, p = 0.019
Figure 1 Relationship between serum IGFBP-7 and IGFBP-1 in
Swedish men with newly diagnosed type 2 diabetes. T2D, type
2 diabetes.may lead to transcriptional silencing of the associated
gene. In this study, we did not find any correlation be-
tween serum IGFBP-7 protein levels and IGFBP7 DNA
methylation. One explanation is that DNA methylation
may reduce gene transcription but not translation [26].
Furthermore, we have analyzed IGFBP7 DNA methylation
levels in blood cells. However, we believe that investiga-
tions of tissue-specific IGFBP7 DNA methylation in T2D
patients or diabetic animal models are necessary to better
understand the correlation of IGFBP7 DNA methylation
with serum IGFBP-7 protein levels.
Clinical observations in many populations, including
Swedish cohorts, have shown that the prevalence and
subsequent incidence of T2D are higher in men than in
women [27,28]. The endogenous sex hormones may dif-
ferentially modulate glycemic status and risk of T2D in
men and women [29]. In this study, we found that
IGFBP7 DNA methylation levels were associated with
T2D in men but not in women. We do not know the
mechanism of the sex-based difference in methylation
IGFBP7, but information from public genome databases
implicates that the IGFBP7 mRNA expression levels are
high in the prostate and testes but low in the breast and
ovaries [30]. Furthermore, IGFBP-7 is known to be se-
creted by adipose tissues and, indeed, a sex-linked differ-
ence is seen in hormones secreted by adipocytes, such as
adiponectin and leptin [31,32].
Conclusions
This study demonstrates for the first time that IGFBP7
DNA methylation is increased in Swedish men with
newly diagnosed T2D compared with subjects with
NGT. Low serum IGFBP-7 levels are related to low
IGFBP-1 and subsequently associated with insulin resist-
ance in T2D.
































Figure 2 IGFBP7 DNA methylation levels in Swedish men with normal glucose tolerance and newly diagnosed type 2 diabetes. Data
were mean ± standard deviation. NGT, normal glucose tolerance; T2D, type 2 diabetes; **P < 0.01.
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Subjects
A total of 340 subjects were selected from the Stockholm
Diabetes Prevention Program (SDPP) and the Kronan
study. All subjects were Swedish. In SDPP, men and
women aged 35 to 56 years from five municipalities in
the region of Stockholm, Sweden, were included in an
epidemiological survey [33]. A follow-up study was
performed after 10 and 8 years, respectively, in the
SDPP and Kronan studies. Both baseline and follow-up
studies consisted of a questionnaire covering lifestyle
factors, a health examination and an oral glucose toler-
ance test. Based upon this test, all participants were
categorized into glucose tolerance groups according to
World Health Organization criteria [34]. For this study,
100 newly diagnosed T2D patients at the follow-up study,
having either NGT or impaired glucose tolerance at
baseline (50 women, 50 men), were selected. These
T2D patients received no anti-diabetic medication
when the blood samples were taken and the phenotypes
recorded. One hundred nondiabetic controls (50 women,
50 men) were selected among those having NGT at both
baseline and follow-up and matched to newly diagnosed
T2D patients by sex and age. In the Kronan study, 140 pa-
tients with T2D (54 women, 86 men) were selected from
three health care centers, Kronan, Hallonbergen, and
Rissne, within the municipality of Sundbyberg, Stockholm,
Sweden [35]. Patients with latent autoimmune diabetes of
adults were excluded in this study. All patients received
anti-diabetes treatment: 24% were treated with diet alone,
46% with oral hypoglycemic agents, 22% with insulin and
8% with a combination of insulin and oral hypoglycemic
agents.
Informed consent from all participants was re-
ceived. The study was approved by the Ethics Com-
mittee of Karolinska University Hospital, and was
performed in accordance with the Declaration of
Helsinki.DNA extraction and bisulfite treatment
Genomic DNA was extracted from peripheral blood using
the Gentra Puregene Blood Kit (Qiagen, Hilden, Germany).
DNA samples were stored at −80°C until use. For epigen-
etic analysis, bisulfite treatment of extracted DNA samples
was done with the EpiTect Bisulfite Kit (Qiagen). This kit
enables complete conversion of unmethylated cytosine to
uracil and subsequent purification in less than 6 hours.
This highly sensitive method utilizes innovative protection
against DNA degradation and ensures high conversion
rates of over 99%. The experiments for DNA extraction
and bisulfite treatment were conducted according to the
manufacturer instruction.
IGFBP7 methylation analyses
The IGFBP7 gene is located in chromosome 4q12. In the
IGFBP7 gene, there are three CpG sites (CGCTCGTGC
CCACCTTGCTCGT, NT_022853.15) as indicated with the
bold letter C and recorded as P1 to P3 (P for position). In a
CpG site sequence, 5-methyl cytosine is followed by guano-
sine, which is the dominating type of methylation pattern in
mammals. PyroMark CpG assay for the IGFBP7 gene
methylation analysis (the detailed sequence information is
recorded at ID: PM00112903, Qiagen) and PyroMark PCR
kit (Qiagen) were used. Methylation levels of these CpG
sites were detected using the PyroMark Gold 96 Reagent Kit
(Qiagen) and the PyroMark Q96 ID Pyrosequencing System
(Biotage, Uppsala, Sweden). Pyrosequencing methylation
analysis of CpG sites is sensitive and accurate [36,37].
PyroQ-CpG software (Biotage) was used for methylation
data analysis. Unmethylated bisulfite converted and un-
converted DNA samples (Qiagen) were used for control
of conversion efficiency of the bisulfite treatment and ac-
curacy in methylation analyses.
IGFBP-7 measurement
IGFBP-7 levels in serum were measured using a novel
sandwich ELISA, which incorporated a polyclonal and a
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Abingdon, UK) as previously described [18]. Interassay and
intra-assay coefficients of variation were 18.7% and 11.2%,
respectively. The average recovery rate was approximately
100%. The sensitivity of the assay was 0.3 μg/ml.
Glucose, insulin, IGF-1, and IGFBP-1 measurements
Fasting plasma glucose levels were analyzed in duplicate
with a glucose oxidase analyzer (Yellow Springs, OH,
USA). Fasting serum insulin levels were assayed by
radioimmunoassay using our own antibodies, human in-
sulin as a standard, and charcoal addition to separate
antibody-bound and free insulin [38]. The same serum
samples for measuring IGFBP-7 were used for measure-
ment of IGF-1 and IGFBP-1. Measurement of IGF-1 in
serum was performed after acid ethanol extraction and
cryoprecipitation. Serum IGF-1 levels were determined
by radioimmunoassay using des [1-3] IGF-1 as tracer.
Intra-assay and interassay coefficients of variation were
4% and 11%, respectively. Serum IGFBP1 levels were
measured by an in-house radioimmunoassay with intra-
assay and interassay coefficients of variation of 3 and
10%, respectively. The assay protocols have been de-
scribed previously [39,40].
Statistical analysis
Data are presented as means ± standard deviation or as
means with 95% CI for normally distributed variables.
Non-normally distributed variables were log-transformed
before analysis to normalize their distribution; their data
are given as geometric means with 95% CI. Comparisons
between independent groups were performed by unpaired
t test or by one-way ANOVA, followed by Tukey’s post-
hoc test. Linear regression analysis was used to examine
the relationship between variables. Homeostasis model of
assessment was used to assess insulin resistance index
(HOMA-IR) and calculated as:
(fasting serum glucose mmol/l × fasting serum insulin
mU/l)/22.5.
All statistical analyses were performed using Statistica,
version 11 (StatSoft, Tulsa, OK, USA). A P value of
<0.05 was considered statistically significant.
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